European Commission steps up protection of European intellectual property in global markets; European Commission, January 8, 2020

Press Release, European Commission; European Commission steps up protection of European intellectual property in global markets

"The European Commission published today the latest report on protection and enforcement of Intellectual Property Rights (IPR) in third countries. While developments have taken place since the publication of the previous report, concerns persist and a number of areas for improvement and action remain to be addressed. Intellectual property rights infringements worldwide cost European firms billions of euros in lost revenue and put thousands of jobs at risk. Today's report identifies three groups of countries on which the EU will focus its action...

Industries that use intellectual property intensively accounted for some 84 million European jobs and 45% of the total EU GDP in the period 2014-2016. 82% of EU exports were generated by the industries intensively using intellectual property. In these sectors, the EU has a trade surplus of around 182 billion euros. Also, an estimated 121 billion euros or 6.8% of all imports into the EU, are counterfeit or pirated."

How much has the US lost from China's IP theft?; CNN, March 23, 2018

Sherisse Pham, CNN; How much has the US lost from China's IP theft?

"The United States has long said that intellectual property theft has cost the US economy billions of dollars in revenue and thousands of jobs.

So just how much damage has it done?

The United States Trade Representative, which led the seven-month investigation into China's intellectual property theft and made recommendations to the Trump administration, found that "Chinese theft of American IP currently costs between $225 billion and $600 billion annually."

Why drugmakers aren’t sweating the next wave of patent losses; Bloomberg News via News Chief, July 10, 2017

Bloomberg News via News Chief; Why drugmakers aren’t sweating the next wave of patent losses

"Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off.

The loss of a series of key patents for cholesterol fighters and other widely used medicines cost big-name drug companies about $82 billion in sales between 2011 and 2013, according to life-sciences data company Evaluate Ltd., forcing large-scale job cuts and a wave of deals to make up for lost revenue...

By the time lawmakers passed a path to market for biosimilars as part of the Affordable Care Act in 2010, the industry had assured that competition would come much more slowly, making the resulting sales decline look less like a precipice and more like a gentle hill."